Abstract:Current reports refer to the role of long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART1) as a tumor suppressor in some types of cancer but as an oncogene in other kinds of cancer. In gastric cancer, it had been reported to be downregulated. However, the clinical significance and underlying mechanism of PART1 function in gastric cancer remains undefined. Here, seven differential expression levels of noncoding RNAs (DE-lncRNAs) were screened from gastric cancer through a probe reannotation of a human exon array. PART1 was selected for further study because of its high fold change number. In our cohort, PART1 was identified as a significant downregulated lncRNA in gastric cancer tissues by qPCR and in situ hybridization (ISH), and its low expression was significantly correlated with postoperative metastasis and short overall survival time after surgery. Through the results of gain-of-function experiments, PART1 was confirmed as a tumor suppressor that can decrease not only cell viability, migration, and invasion in vitro but also tumorigenesis and tumor metastasis in vivo. Mechanistically, RNA pull-down and RNA-binding protein immunoprecipitation (RIP) showed that PART1 interacts with androgen receptor (AR), and then, promyelocytic leukemia zinc finger (PLZF) is upregulated in an androgen-independent manner. In a chain reaction, chromatin immunoprecipitation (ChIP) assay additionally illustrated that PLZF upregulation increased the enrichment of EZH2 and H3K27 trimethylation in the platelet-derived growth factor (PDGFB) promotor, thereby inhibition of PDGFB and the subsequent PDGFRβ/PI3K/Akt signaling pathway. Based on these findings, we showed PART1 plays a tumor suppressor role by promoting PLZF expression followed by recruitment of EZH2 to mediate epigenetic PDGFB silencing and downstream PI3K/Akt inhibition, suggesting that PART1 has a key role in restraining the aggressive ability of GC cells and providing a novel perspective on lncRNAs in GC progression.

Long non‑coding RNA PART1: dual role in cancer

Long Noncoding RNA: Its Partners and Their Roles in Cancer

PART-1 Functions As a Competitive Endogenous RNA for Promoting Tumor Progression by Sponging Mir-143 in Colorectal Cancer

LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells

Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway

Long Noncoding RNA PART1 Restrains Aggressive Gastric Cancer Through the Epigenetic Silencing of PDGFBviathe PLZF-mediated Recruitment of EZH2

Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Roles of Long Noncoding RNA in Prostate Cancer Pathogenesis

Promising Long Noncoding RNA DLX6-AS1 in Malignant Tumors

LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

Long Noncoding RNAs in Prostate Cancer: Mechanisms and Applications

Lncrna PART1, Manipulated by Transcriptional Factor FOXP2, Suppresses Proliferation and Invasion in ESCC by Regulating the Mir‑18a‑5p/sox6 Signaling Axis.

LncRNA PART1 Regulates Colorectal Cancer Via Targeting Mir-150-5p/mir-520h/ctnnb1 and Activating Wnt/β-catenin Pathway.

Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy

Molecular and cellular functions of long non-coding RNAs in prostate and breast cancer

LINC00261: a Burgeoning Long Noncoding RNA Related to Cancer.

LncRNA prostate androgen-regulated transcript 1 (PART 1) functions as an oncogene in osteosarcoma via sponging miR-20b-5p to upregulate BAMBI

Long Non-Coding RNA in the Pathogenesis of Cancers

LINC00958: A promising long non-coding RNA related to cancer

Long non-coding RNA: a new player in cancer

Pathological Bases and Clinical Impact of Long Noncoding RNAs in Prostate Cancer: a New Budding Star